Ensysce shareholders approve reverse stock split at ratio of 1:5 to 1:12

Ensysce Biosciences, Inc.

Reverse split proposal approved with 2,836,326,468 For, 280,656,829 Against, 19,762,315 Abstain.
Board authorized to set exact ratio between 1-for-5 and 1-for-12 at its discretion.
Second proposal lacked quorum and was not voted; adjournment proposal not submitted.
Special meeting held March 23, 2023; only reverse split proposal was submitted to vote.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ensysce Biosciences, Inc. shareholders approved Approve an amendment to the Certificate of Incorporation to authorize a Reverse Stock Split at a ratio of not less than one-for-five and not more than one-for-twelve at the 2023-03-23 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2023-03-23

Exact text from the filing

Proposal to approve an amendment to the Company’s Certificate of Incorporation to authorize the Company’s Board of Directors to combine outstanding shares of the Company’s common stock into a lesser number of outstanding shares, a “Reverse Stock Split,” by a ratio of not less than one-for-five and not more than one-for-twelve, with the exact ratio to be set within this range by the Board in its sole discretion, in the form attached as Annex A to this Proxy Statement (the “Reverse Split Proposal”): For Against Abstentions 2,836,326,468 280,656,829 19,762,315

View on SEC.gov

224 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-008904

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.